Generic Drug Review Costs Still Largely Non-Personnel Related
Executive Summary
Despite a recent hiring binge, FDA's ANDA evaluation expenses continue to be driven by infrastructure and equipment.
You may also be interested in...
US FDA Personnel Costs Drop: Is The Next Generation Taking Over?
The agency sees its personnel compensation and benefits costs decrease for the first time in at least 16 years, while the overall FTE count continues to rise.
US FDA Personnel Costs Drop: Is The Next Generation Taking Over?
The agency sees its personnel compensation and benefits costs decrease for the first time in at least 16 years, while the overall FTE count continues to rise.
PDUFA Workload Sets Records, But Inflation Generates More Revenue
The PDUFA revenue inflation adjustment was higher than the workload adjustment for the first time in seven years.